PI Industries reported a 10.4% decline in quarterly revenue and a 39% drop in profit for Q1 FY27, impacted by weak demand in its agrochemical and pharmaceutical segments. Motilal Oswal has maintained its 'BUY' rating with a target price of ₹3,000, citing the company's long-term growth potential.
PI Industries reported a challenging first quarter for the 2027 fiscal year, with both revenue and profit seeing a notable decline compared to the previous year. The company's consolidated revenue fell by 10.4% year-over-year to ₹1,702.3 crore, while its profit after tax (PAT) dropped by approximately 39% to ₹244.2 crore.
The weak performance was primarily driven by the company's Custom Synthesis Manufacturing (CSM) segment, which saw a 13% decline in revenue. This downturn reflects ongoing pressures in the global agrochemical sector, characterized by soft demand and pricing challenges. Additionally, the pharmaceutical segment reported a significant 25% drop in revenue, further weighing on the overall results. In contrast, the domestic agri-business showed some resilience with a 3% year-over-year increase in revenue, though it was not enough to offset the weaknesses in other key areas.
Impact on Profit Margins
The company also faced significant pressure on its operating margins. The EBITDA margin contracted by 577 basis points to 21.69% for the quarter. This reduction was largely due to adverse operating leverage, a situation where the company's fixed costs remained relatively stable while sales volumes decreased, squeezing the overall profitability from each unit of revenue. Higher input costs and competitive pricing pressures across the global chemical landscape further impacted the bottom line.
Brokerage Outlook
Despite the weak quarterly performance, brokerage firm Motilal Oswal has maintained its 'BUY' rating on the stock with a target price of ₹3,000. The firm’s outlook is supported by a stable order book and the expectation of long-term growth from the company's expanding biologicals platform. Analysts point to a robust product pipeline for the remainder of FY27 as a potential driver for recovery. The brokerage's valuation approach considers the company's long-term growth trajectory rather than just the immediate quarterly fluctuations.
Risks and Monitoring
Investors may want to monitor several factors that could influence the company's performance in the coming quarters. The primary risks include the continuation of weak global agrochemical demand and sustained pricing pressure, which could delay the recovery in the CSM segment. Additionally, the pharmaceutical business faces execution risks as it scales operations. The ability of the company to manage its operating costs effectively while navigating these market headwinds will be a key factor for shareholders to watch.